Module 3 : Diagnosis -Rapid Diagnostics for tuberculosisi detection, World Health Organization (WHO)
Decentralized molecular testing is gaining ground for SARS-CoV-2 diagnosis in India. Due inpart to a robust anti-tuberculosis campaign, the testing modality has made inroads into the country'scomplex and tiered healthcare system during the past decade. Now, decentralized platforms from firms likeMolBio Diagnostics and Cepheid, as well as newcomer Tata Group, are starting to play a significant role inCOVID-19 diagnostic testing in India as well.
NEW YORK (GenomeWeb) – MolBio, a Goa, India-based molecular diagnostics manufacturer, is bringing tuberculosis testing closer to patients in its home country, potentially competing with imported testing. MolBio's point-of-care real-time PCR system and infectious disease assays are currently commercially available in India, and the Foundation for Innovation of New Diagnostics (FIND) is now assisting the firm with clinical trials of its TB test system prior to review by the World Health Organization for potential prequalification.
